Searched for
GENERIC ADVAIR
Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
- Aurobindo Pharma launches generic Advair Diskus for asthma and COPD in USLannett Company, part of Aurobindo Pharma, has launched generic Advair Diskus in the US, making it the first complex inhalation product fro...
- Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTDAurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The i...
- Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
- Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...
- Cipla stocks dive to 7-month low; here’s why bears are ruling the counterIf they are minor in nature, then it is unlikely to hurt sales from the unit. However, if the regulator found major deviations from good ma...
- Cipla submits application with USFDA for generic version of asthma drugDrug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...
- Cipla jumps 8% on completing Phase-3 clinical study of asthma drugThe generic would be used for treatment of asthma and chronic obstructive pulmonary disease.
- Cipla’s India revenue grows 13%: Key Q3 takeawaysTotal revenue increased 9.06 per cent to Rs 4,371 crore during the quarter under review.
- The colour purple that has left drug makers like Dr Reddy's Laboratories paleThe reference here has nothing to do with the Pulitzer-winning book of Alice Walker, but the actual colour that has pushed big pharma to pu...
- Cipla slips as rival Mylan launches generic Seretide in UK's $400-mn anti-asthma drug marketShares of Cipla fell nearly 3 per cent intraday after rivals Mylan launched first generic version of anti-asthma drug Seretide.
- Lupin ties up with Poland-based firm for generic asthama drugLupin has set up a dedicated centre of excellence for inhalation research in Florida after having hired top notch inhalation scientists las...
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.
- Brokerages raise Cipla's target price post inhaler launchAnalysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.
- Lupin to file new drug application for GSK’s $8 bn blockbuster inhaler AdvairMumbai-based drug maker Lupin Pharma will file an Abbreviated New Drug Application for GSK’s $8-billion dry powder inhaler Advair, said Vin...
- Brokers' Call: ONGC, DRL, Cipla and Coal IndiaWe have compiled stock views and recommendations from various agencies on ONGC, Dr Reddy's, Cipla and Coal India.
- RBS recommends a 'Buy' rating on CiplaRBS has recommended a 'Buy' rating on Cipla with a target price of 360.
Load More
